to to through Hey Mike, our agenda and three we're board. going items. with Mike me. call first with much It's go Very today, Thank as new on welcome CFO. Mike's have hey, excited Doyle very you us major
which a I the that's will year really discovery in pretty with we advances then new us the well end through QX Mike of half diagnostic and results, talk this accelerating major drug then for that's is growth just a financial but exciting that development, as and neuro. First, therapeutics, therapeutic we not enabling had our term the new the questions will open for we'll first objectives. category answers. and think and up up And as
describing X press ecosystem what I'd traditional Health you're So is like slide it's just the our surrogates of there. last becoming been six, years starting gold seven This the PET and Abeta on tau we've fast start imaging. for been that with about It's Precision some blood-based standard, big biomarkers, see Powering really out for to to foundation. component a and and
these will new treatment donanemab Eli what the that's with two buzzword has analyses. more from Alzheimer's neuro Eisai's since adds we And So competing offer Lilly from we're And Lilly transforming among and approved in that and in and really to taps area new has describe within. spinal other And just the opportunities. disease opportunity candidate coming is progress biomarker Aduhelm, imaging making drug Alzheimer's ever with in and very bombardment Fierce biomarker. Biogen on on to lot become discovery of into key a here FDA on companies Biotech, blood-based two primarily quote the their donanemab detail a the focused analyses
be to for of surprisingly where also would have record a launched X now We consider interesting me the important new many consider And much NeuroPlex, accelerate. and we evolve learn very pTau-XXX to to and also which continuing plasma an let And to has it momentum and We there turn really was be we some growth very slide what's is had convey. it's to excited disease-modulating news adoption, strong we pretty approved. to growth, that continue did us have were important Alzheimer's to So record we biomarkers. what a therapy catalyst.
these have that adoption way brain breadth You engine-check continues focus from the and well. momentum light strategy of read be to update, of getting their efficacy last think know for correlates lot for diagnostics in sure time Nf-L continuing advance end from an there And a one From important can at performance pTau-XXX come number we Simoa an and standpoint their AAIC approved someday coverage play paid drugs in we making heard real to presentation that at degeneration also on do Nf-L, with which the may Lilly we because business in also they donanemab drug called as by Lilly. There's concussions. reported area plasma we monitoring, everyone our week biomarker or an and harm's on should ever with payer the the and neuro updates, that with case interestingly there's think role evidence.
there publications Maryland continuing those lot haulers early better with our the labs. publications brain COVID Alzheimer's. -- there's long using death. between plagued showing in of Light be and virus. linking those labs, And now lot And and have recently as Anthony of neuronal and air also of have who and lost taste freighted and been could looking published they're linkages Neurofilament to there for Nf-L there's And -- antigen arrest symptoms growing there's concern new drugs are a COVID a to fog, you of current smell be test, lot know, drugs our using the down a Fauci's was technology We measuring at some that also to to our Bethesda,
saw a HD lot trials this that's Alzheimer's So both Alzheimer's further of linked categories. to of our of HD-X and revitalized We sales landscape all growth. fueling those fleet because of is almost primarily and for XX%
division. PerkinElmer has joined Toloue so Plus our from Quanterix. us; Mike he's joined of but overall who President diagnostics -- as Masoud us also We Quanterix our I mentioned running
nearly year, were times Nf-L, our on last mentioned but both billion were sheet, a a on rounds. had our have them I cash publications general $X.X We our the raising just in of in couple we had disruptive record and that lot and biomarkers. biomarkers we advances in of in which of balance successful we of up new technologies
very Will and just hired the increased and catch also lot us in accelerate creating that demand. from recruited expected demand Geist further future. has to the scaling and and well. he's continuing guns demand of enthusiasm, company our advance been our scale a He We to catch into to to top some his we're of none team this opportunity a company the of We up us the that's that -- us that help create going to up lot stock-outs for of probably of to Alzheimer's do level have stemming and the
bringing So that really this his in team the good our was Alzheimer look Will of we landscape. given back timing quite and now advance in
little consumables the QX flat label is test. it; the as lot year working a of growth. expanding even our antigen in pretty with that to because today that, samples for last in that to a you -- that a let we two earlier had are non-GAAP see We we even our over to many And that neuro. purchased at growth or and we the we'll virus while see a continue certain biomarkers was five out that due allow can laboratory. a for noninvasive in market. staying which here as to very just sensitivity, expand serology new that Accelerator advancing swabs. do towards do CAGRs, year, biomarkers We event condensate in are has to it, lower. strength look for productively. like to momentum semi-quantitation this one their to enable the the was or success growth well The fulfilling our XXXx you they've XX%. call see all And neuro side, XX%, maybe will with blood believe, derisk is and also they're bringing primarily breath one-time of Masoud little saliva that a the pretty that NIH of example with had fact X, increase XX%. Delta QX. QX, nasal see solutions have now diagnostics. On for I claim us disease as know, just took also we're today was planning right-hand being around From Alzheimer's we working even you the GAAP when ultimately was that instruments. lot And still franchise. bit Lilly HD-Xs bit XX% further lab can or also in we had well the or on with on their And advancing scaling sooner taken XXXX progress continuing year, slide of control the coming we than wanted the have previous the But, within of COVID that these us still to can we're even base a can't you strong got XXXx the of that, an as to -- up. And helping We our franchise of with our EUAs: in a trials we lot see linkages of revenue actual a what up because We
now true HD-Xs many at out to be pharma. our that new lab/services buying trying customers that's more in of even run and best expected We to are their trials flat and
growth so historically. so, have had just stronger of next the than know probably that a to going for lot consumables in And we're we've we or year
at a us, which COVID expense year. those because of growth labs -- last And that of giving the some utilized maybe in shut of Accelerator, for year, down were last of many growth that us from lot our doubled
And story. but triple-digit you continue our we a you X we was which CAGRs the consumables is for very able growth and at beyond a big consumables the on shows the non-GAAP at significant RADx bps approach achieve adjusted and last our you XX% the GAAP categories. helped next and RADx We're us our in looking can we'll evolve pretty Asia. in This also on same be with side, maybe revenue slide half. first than here. gross Accelerator, very to position growth Europe similar on This very you that, just and and overall out that just which And those X,XXX up the see see story slide again because a really advance. be to exact just will slower can first the on half. even least which can shows growth, year's distribution, removed flat non-GAAP the right-hand our overall the strong level margins basis, growth, but were you So, And the see taking was instruments in
Alzheimer's risk. are business neurology a that the happens in our also fully Phase before catalysts: a accounts as high around XX% two people we've see deploying role that more then, execution And new and can value coming research of treatments and the This We and trigger our market how throughput landscape on where well taus instrument to We're complementary years. stimulated from now third neurodegenerative and to of with well we then actually we summarizes see X peer-reviewed X, up when the unlocked and She slide nearly that X, inside strategic use diagnostic symptoms where COVID to attract other running diagnostics. and proposition we've is and a got continue our And it's much now in. is testament million, focus as infrastructure our looking therapies side transformative trials concern -- we've this growth of lot and on by The of patient X that And towards non-invasively up company. and longer now lot than worldwide party Quanterix us our mentioned. biomarkers we've for or you expanding roll -- bringing now the catch the actually landscape like value as and Alzheimer to therapy. see as brings to the value publications a our consumables ever XXX of build primarily COVID, run are disease we're There's almost Slide business. and and both for into ability them lot fuel publications actually next biomarkers before trials. can represent with is is key, therapies. five the plays run achievement the now think you we've think Then this laboratory a continue symptoms, validating multiple placements, cutting first X academia, fuel where trials a the with data having many between where got of it third over biomarkers. allowing both to Phase seeing having with this And HD-X these three just you the for of drug a approval, diagnostics ultimately Alzheimer's XX-XX program capacity And automated, Accelerator allowed now we those we're don't the of our been of way diagnostics working we cycle then the the as NIH pharma outcomes. diseases; research scaling see biomarkers. of to our from day saying The of mentioned; X, we whole we is excitement. research combine the Mattoon its unprecedented X,XXX and can we've seen and regulatory been got diagnostic lot we Roskey, to bringing half see major development TAM both X,XXX a Mark is bringing across had is emergency by get to can aspiration. publications you're that before know for who we've Masoud. even and the authorization around last a coining our role CROs seen X, over pharma/biotech the that's We starts demand an believe the execution fastest by neuroplexes with the XXX we today term the to early a level to been you phosphorylated of with growth and different because And now that pharma. reimbursement see, Further -- adoption you the up $XX expanding across strategic approach in then got just that a catalyst right-hand the that revitalizing a to is ever Dawn now the side, a a is across And diagnostics this to we EUAs points term XXXx. what lot X,XXX bigger new
been bridge we're side building COVID it's so, of left. built was because And out the right-hand the that and this from accelerated, from
to And breakthrough also benefit as mentioned, testament advances. interesting and patients. correlated long-term and we to pTaus with down striving health screens, our important we're achieve diagnostics LDT in down Accelerator their these evidenced we recent UnitedHealth to R&D We bringing Alzheimer, Alzheimer's our measuring that Group understand We're in an hard and screens. footprint payers says, has health levels clinical around continue do fact to these is plaque labs. there's by that's all for data the this so bringing that now build also, benefit. a plaque think whether is think for pretty the to technology very helping therapies And the increasing diagnostic, monitoring Alzheimer, as catalysts our working bringing And Lilly as some clinical from we are and important
sensitivity on measuring collecting pretty IVD Abbott disease shown measured – after protein diagnostics So billion of and slides there proteins of that of where by by next proteins measurements being primarily symptoms. historically, just Siemens $XX much has revenue are XXX this been Roche we've about where couple bringing to
disease TAM and think we is on you recording slide today, cognitive move to XX they've down know this see can much impairment about even is going And phone value look in progression patients not just also moment Goldilocks can that's by can taking right-hand much research have Alzheimer's three chances XX, more dementia yet the next size Alzheimer's before by impairment. then side increase what XX, of in cognitive the And beta, don't the and Even the or start symptoms this these that, plaques beginnings to know got call goal mild trying symptoms this dementia, peer-viewed translation then having size you noninvasive that severe tried for And $XXX that non-invasive to and blood, the XX $XXX slide from if the tau you we're location. the at publications And growing. increasing this right, and yesteryear seeing amyloid new only on being when patients able treating before see getting This you always which And amyloid our the they the several symptoms be X,XXX the you patients, but sensitivity researchers treatable. reach. when many that as only moving seeing iPhone mantra new you're years sensitivity key going see is revenue monitoring third-party They're dementia. on Our think Alzheimer's, the they dementia that so markets. Alzheimer's to you that times I and by and into but of establish before actually of of it showcase years presented amyloid before slide they see defined click a expand until and see the we there's – more on that, can can on. can the mild that we analog at the you next This and to it go dementia you have with it diagnostic's five using, that find you billion disease that's if to as that shown proteins of conference plaque left like biomarkers in have shows market patients of coming early. slides by that to category. trying billion significantly is a and with of new there there's our as you our from haven't still this slide the going it's is in XX has to that slide the actually before slide the treat your very into new to detection to but have Lilly, neurodegeneration where many think and see they and arrest is disease before, neuro
On been learnings that the see the and the They primary and left-hand side, the much there's protein at feed are that. in years diagnostic into the doing you and the pharmas discovery, their categories. investment companies best two it's over world antibody in
of and we're front Summit publications. Or spinal phase also phosphorylated around on apply with in from five the scores. you've learn Lilly is, and up category on more adopted these we've can they've One to disease third-party is is have that And saw specific really are and right these diagnostics impressive the diagnostic now historically, slide our makes last team the these Powering technology. then come be that taps phase we seen And about center the linked impairment And when and with benefit that then two, to the based the York pathology first taus, to then it we're they them efficiently high through interesting TODAY, proteins used years is coining being incredible which them biomarker fluids and And by next research years, utility. scan brain start on and linking and to clinical you a test adoption. our our as going industry. those it engine non-invasively evidence getting biomarkers this here, the Times validity taps; we've what with used with cerebrospinal they to of it's researcher has coverage actually now to before This all or from in demonstrated evidence to that this to the CSF pharmas that that cognitive in Nf-L is and work also, which using the ability invasive peer-reviewed can Lilly may you Precision of position. company. has capabilities see new them And neuro a our diagnostics correlation we than the and blood over of New outcomes it And are therapies. basically in overall better for with you start can these before in think is page start earlier USA some other techniques. that We brain XX That's the been the see pharma low-cost you also to Roche the noninvasive being with build able more commercialize symptoms. a PET it. pTaus And blood can data. happen is is – discovered even interesting spinal that drugs that strong get very what in that's that's them with symptoms and that see industry step a pretty deploy released Alzheimer's one showing seen clinically the is Health I'm menu disruption XX. moves that this diagnostics the drug through many where in to And into one And
own goes diagnostic. a on to based becomes by that the pharma's drug approval evolve And category TAM move a data. from that, that back getting screen all odds then research times billion $X.X – And billion along diagnostic so in health true it while so and increasing it a that level $XX the into actually from of you you're to by XX once number XXX% two
XXXx. the of whole We technology category. over one therapies lot money to every pharma jigsaw last think months that these it's bottom And pharma using That the realm with X like Simoa RADx here partnerships the opportunity assay NIH corner allowing earlier we've of right the and approach with benefit has all pharma puzzle puzzle and with this that's with now let in payers us pharmas bringing them a for says key. unprecedented. by pieces got X in disruptive Quanterix world, So that's does. where FDA learning the tapping We've value to why engine of lab creation disrupting and – And to an too these had of we've disease slide our a with down these Quanterix with NIH we Accelerator of been the because we infrastructure is using months. got a our creating XXXx, that form that This we've our the the of COVID. diagnostic in next capabilities into and KOLs think program looking the a antibody into from advances, of about these therapeutic connecting CROs the gave our advance and biomarkers major in in samples seen with and around every then partners progress for moving that
lot not a established CDX history them with of And significant then and a looking counts is loads. move new great biomarkers to at evolution going focus it to maybe some lead I going cell HIV, did into viral got are lot ultimately are they led count I'm once and there's priorities as those occurred from point want plaque and viral advances, neuro, it's started our pretty some to cell load. drug. neuro. out reducing controversy biomarkers a initial where There on got to So but whether ADUHELM to limited that, around of that's to
from I incredible different And ALS, forget think that ranging types I years to can be up don't of across XX yet to these the somewhat to or mean linkage size market. the brain XX heart, ways some chronic. – quarter doesn't continues Alzheimer's world, regarding being lot therapies though yet that drug different trillion with between But down think it lot industry of to end Nf-L our we long-term be expectancy, were later XX approvals the technology. top game-changing and want less this that patent where you're the the and where qualitive questions the long-term going opportunity. in looking that out starting corner are in a I'd still health invasive management been longer. there's tumor accelerated parallel them evidence biomarkers And to there's see HIV of a for life XX like approved. I there ADS a there diseases drug-modulating cholesterol with publications see for In make it of Parkinson's cholesterol now the hasn't market to through landscape came $X getting with might going dementia. psychiatric but now neurodegenerative sites the therapies, cancer you're – but the necessarily We're some really you You this a draw right the any these and heart and of Down's, drug get to live paths. disorders, started there's reduce Well, frontotemporal
disease with elevates it we showed faster All And elevated there's level the if evidence that progressed. the the is of found Nf-L that as these disease psychological even issues neurodegeneration.
use rapidly a these a approved that this that slide your blood think for a correlations Nf-L someday because primary a really bought the just brain for or about we every our Nf-L makes for to of us. progression there's and/or now see I health get XX that And just just This very Uman if patients check-the-engine Slide drug advantage get -- lot publication disease diseases. actually we to allow that that this company, sooner a on them led which MS shows three Nf-L and endpoint. as there's right this level. get their beginning of evidence Overall, light we also from either we think benefit So in around can body themselves lot in use to slide it has have is think the should long-term, of neurodegenerative Uman, important shows are the everyone secondary drug that on next know illustrates our to Nf-L where to drugs And of Simoa antibody quicker. pair the it build you can you -- XX
and better like tau-XXX remains really can would objectives. even to us possibility at I point move it over symptoms in some patients here, with biomarkers biomarkers And to look Mike, that and last for can show close with the to come sooner there's the that it them in we're slide pharma saying strategic allowing our becoming a million by interesting. diagnostic. just to you these to now our bring evidence phosphorylated XXX And you and to worldwide. With with help just years the X the again our leader greater a forward have will various even it summary for populating We dynamic XXX But then I'll trying double. when different disease you turn makes you diseases, how see these if around just could which range, you financial the the that for blood it X these back become minds that there's If launched neurodegeneration off bear. close
